In the former trial, the primary tumor load and lymph node metastases in group A were more serious than those in group B. In the latter, only 2% HER2 positive patients received targeted therapy, and only a minority of patients used paclitaxel during early rescue chemotherapy (14, 15). Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.